Efficacy of an Integrated Psychological Interventions Combined With Ar_Rahman Listening for Reducing Psychological Distress and Enhancing Hope and Quality of Life Among Cancer Patients: A Randomized Controlled Trial

September 16, 2026 updated by: Mobeen Mehmood, Shaheed Zulfikar Ali Bhutto Institute of Science and Technology (SZABIST) University

This is a randomized control trial(RCT ID:25142101) to evaluate the efficacy of psychological intervention combined with listening to surah Ar- RAhman for reducing psychological distress and improving cancer patients' hope and overall QOL compare to standard care. participants will be randomly assigned to two groups: intervention group will receive 14-sessions based manualized psychotherapy plus daily listening to surah Ar- rehman for 12 weeks, and control group will receive standard care .psychological distress will be measured with DASS-21, Quality of Life (QLQ-C30) for assessing Quality of life and Adult hope scale for assessing hope before and after the intervention.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

this is a two- arm parallel randomized control trial. Background: psychological distress is common in cancer patients and affects treatment outcomes. spiritual and religious interventions, particularly, listening to QURAN recitation(Surah Ar Rahman), have shown potential to reduce anxiety and depression giving hope anf improving overall QOL.

objective: To determine the effectiveness of psychological intervention combined with Surah Ar Rahman listening in reducing psychological distress and enhancing hope and Quality of Life in cancer patients Methods: approximately 60 adults cancer patients will be recruited and randomized(1:1) into intervention and control groups. intervention group: 8 weekly psychological counseling session (30-45 min) based on supportive psychotherapy and CBT techniques plus listening to surah Ar Rahman recitation by Qari Abdul Basit (20 min daily). control group : Standard medical care and general information. assessment at pre and post intervention .

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
      • Islamabad, Pakistan, 44000
        • Oncology department, IMPS, Noori & Shia International Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Inclusion Criteria

    • Aged 18 years or older
    • Have a confirmed diagnosis of cancer stage I and II will be included to obtain a relatively comparable clinical population and reduce variability associated with advanced disease and palliative care needs.
    • Are currently receiving or have received cancer-related treatment, such as chemotherapy, radiotherapy, surgery, immunotherapy, or other oncological treatment.
    • Education level will be matric atleast
    • Muslim patients
    • Able to communicate and provide consent

Exclusion Criteria:

  • • Severe psychiatric disorders

    • Cognitive impairment
    • Hearing impairments preventing audio participation
    • Physically unfit for this study's interventions (for example who are bed-bonded or too weak to engage in the study interventions)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: intervention group

participants will receive 12 week of psychological intervention weekly(30-45 min) counseling based supportive therapy plus daily listening to surh Ar Rahman recitation (Qari abdul basit, 20 min) via audio player.
Behavioral: supportive psychotherapy plus QURAN recitation9Surah Ar -Rahman

participants in experimental group will receive 12 week psychological intervention : weekly 30-45 min counseling based on supportive therapy plus daily listening to Surah Ar Rahman recitation ( Qari Abdul Basit , 20 min ) via audio player, participants will be provided audio and intructed to listen daily and maintain a log.
No Intervention: control group

participants will receive standard oncological care and general health information without psychological intervention or QURAN recitation

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
psychological distress (DASS-21)
Time Frame: baseline and 12 weeks post intervention

Psychological distress will be measured using DASS-21, a 21 item self-report instrument with 3 subscales: Depression (7 items) Anxiety(7 items) and stress(7 items). each item is scored on 0-3 Likert scale. total score range is 0-63, Scores of each subscale are categorized into five severity ranges: Normal, mild, moderate, severe and extremely severe. For depression normal range(0-9), mild(10-13), Moderate(14-20), Severe(21-27), Extremely severe(28+), for anxiety normal range(0-7), mild(8-9), Moderate(10-14), Severe(15-19), Extremely severe(20+),for stress normal range(0-14), mild(15-18), Moderate(19-25), Severe(26-33), Extremely severe(34+) While the scores do not provide a functional diagnosis, they indicate the potential presence of depression, anxiety, and stress
baseline and 12 weeks post intervention

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Quality of Life -EORTC QLQ-C30
Time Frame: Baseline and 12 week post-intervention

Quality of life will be measured using European Organization for Research and treatment of Cancer Quality of life Questionnaire(EORTC-QLQ-C30) Version 3.0. it is 30-item questionnaire composed of 5 functional scales, 3 symptoms scales, a global health status scale and 6 single items. scores are transformed to 0-100 scale. higher score in functioning and global QoL indicates better QOL, higher score in symptoms indicates worse symptoms
Baseline and 12 week post-intervention
Adult Hope scale(AHS)
Time Frame: baseline and 12 weeks post intervention

hope will be measured using Adult hope scale(Snyder et al.,1991). it is 12-items scale with 4 agency items , 4 pathways items, and 4 distractors. items are scored on an 8-point Likert scale from 1- definitely False to 8= definitely true. total score range is 8-64. excluding distractors. higher score indicates higher level of hope
baseline and 12 weeks post intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Shaheed Zulfikar Ali Bhutto Institute of Science and Technology (SZABIST) University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 15, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 30, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 30, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 16, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 16, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 22, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 22, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 16, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • SZABIST-ISB-25142101-RCT

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

individual participants data(IPD) will not be shared due to ethical restrictions and to protect patient confidentiality as per institutional review board(IRB) policy. the study involved sensitive psychological data of cancer patients. De-identified summary data maybe available from principal investigator upon reasonable request after publication.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings